KNSA - Earnings call transcript Q3 2021 | Kiniksa Pharmaceuticals, Ltd.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals third quarter conference call. At this time, all participants are on a listen-only mode. After the speakers’ presentation, there will be a question and answer session. To ask a question during that session, you will need to press star, one on your telephone.

assistance call, any zero. press require you during please the star, If would the today, hand like over I to speaker conference now to your Ms. Frank. Rachel Ms. may you Frank, begin.

Rachel Frank

you press financial our Investors results you our recent found and to Thank on pipeline website our these and morning and activity. results and Kiniksa’s be A discuss XXXX the joining highlighting Media call thank quarter third corporate Good Operator. release under for section. everyone can

third K. update agenda, for Patel Ross and Sanj Eben the Officer As on Arcalyst session, Officer Chief our with quarter brief Business XXXX Mark an will remarks of Chief Officer, closing Sanj will for commercial Chief start our be Chief introduction. Ragosa, a off will to our pipeline financial will Moat, which finally Commercial our Executive Financial the with return Medical to will also on launch; Head review Officer kick and Paolini, our Q&A line. review; Kiniksa’s follow provide John results, Tessari, an the will the

note to these and of statements law. started, of presentation turn our These such over Sanj. statements statements and cause filings. that on found required uncertainties and results this factors by contained undertake speak to SEC as may under will materially of forward-looking statements be I as With in Risk as please review the today caption will as well to date that Factors the no it that except getting Before actual only that, update differ we can be to risks statements. making A are from subject we risk such this slide, obligation

Sanj Patel

morning review quarter Good I’m results our Rachel. today. third to everyone. Thanks XXXX happy

to XXXX $XX.X we’re to make delighted our executing million. quarter product of across the for also of and patients bringing continued need, was candidates. clinical to that I’m Arcalyst tremendous for report net third stage portfolio We in revenue Arcalyst in progress

in in As expected, sales. growth moment. detail more will major the recurrent commercial cover Arcalyst driver pericarditis for a was the QX performance Ross our

with commercial driving are Arcalyst. reimbursement underscore adoption targeted our pericarditis pleased core are need the what’s and sales This very broad We and significant the and includes of physician the elements viable recurrent conditions. patient implementation These strategy. for

focused the Additionally, building our we value and KPL-XXX, of are remain vixarelimab, candidates, our stage on and across product CDXX portfolio maximum program. mavrilimumab, is which clinical these

opportunity We ARDS, continue COVID-XX III first in data to expect a and this later. in little Phase potential will population of the of and XXXX related our mavri quarter patient Eben the from highlight trial

progress continue I’ll be positioned portfolio growth. in longer we energized We to over detail. Ross? term now Ross to discuss well that it our to our by and performance commercial we turn for more across the are entire believe

Ross Moat

Thank you Sanj.

very in inventory second QX. quarter recurrent momentum of million. than not in the of approximately revenue recurrent one-off in million we the $XX.X build did stable QX. the QX $X.X expected, remained indications that to in launch of of of one-third QX; grew as demand quarter repeat base a and more million the in DIRA QX, our saw from a pericarditis Revenue report and therefore, to anticipated, thrilled was launch, as This continued and net growth We’re revenue shape major great ended CAPS that XX% positive $XX.X with growth the of and, quarter-on-quarter with driver from pericarditis in represents a three-quarters

On detail will trends, and pericarditis drivers Taking cardiovascular and rate between early we dive from with and growth. Slide I a this have million launch more of into recurrent behind continued in and of it into uptake patients adoption million. ultra-inflammatory payors QX net physicians, $XX the disease. delighted provided previously are revenue debilitated the on consideration growth the guidance represents the $XX We unmet X, Arcalyst and

broad continued recurrent the is there the awareness with had since than end pericarditis more of the for more who XXX launch. pleased physician very growth rapid in QX, Arcalyst. the prescribing written of were unique and breadth double Arcalyst of are QX, adoption. prescribers in we reported demonstrating This than At We number

starting initial prescribers prescriber also face. to launch, recurrent we are have we highlights to We an commercial see physicians, other Since engage hear about to are Arcalyst. X,XXX the physicians remotely, Furthermore, than This has favorable around as who XX% writing our accounts. interactions while are the XX% more in are these with the in patients. of pericarditis eagerness to increase target continuing multiple to of for achieving many excess we team many engaged as representing of companies the learn well of access face target accounts

to continue recurrent of we side, payor the approved all that see XX% more coverage. were pericarditis for than patient On enrollments completed

now is confidence encouraged This when that also We’re in report for and prescribing policy the quicker expectations having in target coverage gaining pleased for our access physicians coverage greater pre-launch and have payor than achieved access broad finalized a U.S. to than to allows XXX of we place. million favorable lives with a patients. our higher the and population, their

breakthrough with XX it’s on that it’s updates our Arcalyst previously excellent of as how campaign. one of receive to payors how therapy and to give are more tools still of disease policies that recurrent end the the the patient the the on on them quarters. anticipate marketing social Around about treatment two-thirds to approximately campaign, the have patients that expect to payor a prescriptions education we Arcalyst physician interacting believe fall patients a education coverage U.S. recently continue of and update therapy, breakthrough initiatives, the will their currently opted who on and we almost that strength Arcalyst When duration. too pericarditis; all on professionals therapy reflects were desire built who On willingness pericarditis promotional recent long across a which to provides of to lives. I provide recognized the still for tailored behind the have and on of normal approval pericarditis the patients we’re Arcalyst. further patients resources provide help and important caregivers and duration QX early in well stated, underlying we of remain for through of compliance, how the Arcalyst advertising, and it their months launched X, journey within launch, and is however, ask remaining are treatment were initiated Through and treatment. pericarditis patient’s on targeted is like for communication of the as we plan database driver almost about disease national generally are dependent recurrent return far, in We this disease. marker and written patients to disease to treatment our of definitive for Slide the time truly all in XX information We the comes in and thinking patients would additionally, data with QX. underlying to Arcalyst to recurrent year approach local weeks, the of becoming This designed treat and a their believe healthcare recurrent duration from reach receive In this to to the targeted coming As therapy. will ultimately stage a group on the refills specialists seeing this the media to duration initiated to state to to whilst an on as we we campaign webinars, at so highlight of X,XXX will database our their new promotional patient depend in patients

and is team fact FDA on launch. the to an Arcalyst pericarditis is need examples successful drug and so debilitating to the and These quotes focused an are Arcalyst. Recurrent Kiniksa a have this share approved patients that remained in for and are painful disease, to completely disease. patients perspective and Moving are I recurrent Arcalyst XX, patients’ Slide incredibly on wanted focused directly only secure we and of why first some from pericarditis from the driven example the

are to normal We this break to disease their here and for lives. patients to through support get back

and in foundational from to to and the now quarters for approval, we forward with delighted results QX continuing and strong we patients Eben, to beyond. are We have deliver two look you. QX over

Eben Tessari

will with everyone. Thanks a overview where stand I we good with vixarelimab. our provide starting morning and brief programs, Ross, on clinical stage three

from worst key change hyperkeratosis, cytokines dose once-monthly dosing are We itch implicated in the trial which is is endpoint two global data prurigo half this a that testing targets of regimens. second The ’XX. currently and placebo-controlled in enrolling fibrosis. NRS different OSMR-beta, in primary we the efficacy and three This first-in-class Phase randomized in at nodularis, trial week XX, pruritis, expect mechanism mediates a IIb ranging

KPL-XXX, of this a trial also plan by chronic potential enable is KPL-XXX but a patient characterized, has an the not pathology early Phase characterization signal end also to autoimmune only II in year. arthritis trial well signaling. The initiate study well from response be therapeutic in evaluate believed across results designed the to in PK XX-week where and RA we RA been a dose For disease this is patients to a provide proof-of-concept by to range mediated described of optionality with of efficacy administration population. with diseases CDXX of this rheumatoid may

data utility of across has through slides. demonstrated indications, mavrilimumab, the including arteritis by COVID-XX two giant next positive encouraged potential Finally, in and multiple which we’re related previous clinical the cell which I’ll walk ARDS, broad

market variants despite the resulting cases the the vaccines the of hospitalizations over the around limitations limited. in average hospitalized represents Turning to for in for the population once and the We’ve of remain being Slide average. seen terms of vaccinated, a patients fully and influenza, significant U.S. which pandemic availability, rate the are hospitalizations Since remained XXX among emergence options XX, hesitancy the of above even XXX,XXX we vaccinated and of pneumonia multiple-fold has patients of and are of onset individuals, year of hospitalized million and treatment historical therapeutic in the believe per hospitalizations will resulting with upsurge opportunity. on

months the six fully second-highest began, hospitalizations having last million of seen context in million have pandemic XXX and Americans of this, the been the vaccinated. that’s of between since evidence the and surge As XXX

turning than that vaccinations for seasonal to ARDS will hope remain I significantly the reduce may several want and which in we to both come, While influenza and data. next higher rate our trial in antivirals we III have come, of years program that some expect market the outside XX, rate is With the we Slide fully the to mavrilimumab hospitalizations highlight which ARDS, Phase in COVID-XX context expect the U.S. for and to to the

on a patients is mavri therapeutic with here believe slide, data, we related and shown II our for differentiated Phase best-in-class this ARDS. As COVID-XX based on potentially

been relative mortality data Phase This Those pharmacokinetics in confirming in mavrilimumab, the up versus prolonged could a or being XX also absolute study As given are single in cover substantial XX. on quarter over XX August, In end the portion With with expect II is prolonged outcomes of turn Phase ARDS in financials. of had patients the we our data. of In Day plotted of ventilated data same over at of Day benefit results other showing strongly the previously risk data carried of was the administration that demonstrate here, our survival setting, April, mavrilimumab and mavrilimumab if III. Currently, reduced either quarter extending the in ventilated time, of reported looking positioned which the on II placebo. Day the mavrilimumab on Day and mortality the confirmed we out I’ll from we persistence hospital cohort hospitalized, reported published market non-mechanically the the death first trial Phase to patients consistent reported overall reduction through non-mechanically Phase by this thus we’re COVID-XX call ’XX. versus X. XX% in that, now third the related of that to Mark focused completing of effect III data

Mark Ragosa

our review going I’m our for through Good financial Eben. Today to quarter performance third of XXXX morning the guidance. everyone. and Thanks walk

financial to in release, call few attention your information can to our find today’s You like items. and a I’d detailed press

third doubled lives XXX First, anticipated States. by covered driven revenue of well primarily with stronger quarter million as United than Arcalyst greater million than in market sales as access was which initial more already in recurrent sequentially, than the $XX.X pericarditis,

$XX execution million upon strong quarter net million third Second, in of based this between revenue Arcalyst sales, we year. total expect $XX date quarter fourth of to and and the

sharing on CAPS Third, Kiniksa XXXX, When and the approved In DIRA, evenly within third sales as separate a of a sales including responsible Arcalyst the will profit be collaboration reminder, profit we Regeneron. profitable, of collaboration and make profit the splits and is expenses. with for a did for quarter not indications reflected item sharing as States, operating line distribution United payment. in the

of quarter fund of the reserves Lastly, that, period of million net to for our loss to last With we $XX.X for for million, we and the $XX.X year, XXXX the third current third million into quarter the compared XXXX. XXXX to closing Sanj $XXX was to approximately I’ll plan ended expect turn cash which with back operating remarks. same call continue

Sanj Patel

Mark. Thanks

focused Slide last It’s the for across to time on Turning the XX, are building slide, the value exciting is our Kiniksa maximum which a company. portfolio. at we very

patients recurrent for pericarditis. validates feedback with a The maintain continue positive therapy. receive and to need the from to continue We strong start physicians launch we Arcalyst this of the in

and we to our beyond. by year are that previously, we throughout energized portfolio believe well this mentioned I execute and progress we our are across As positioned

by vixa We and and range potential prurigo of seen nodularis, are of utility COVID-XX mavri, in KPL-XXX’s encouraged broad in the today autoimmune in diseases. GCA,

to Importantly, our Mark the have to I we XXXX. your current reserves thank to into well operating all are are million and today, With expected mentioned, call fund turn for want as you we I’ll of that, the tax time Operator. capitalized and $XXX back that plan very

Operator

Anupam first [Operator comes question Rama from JP Morgan. Our instructions] of

Your open. line is

Anupam Rama

quarter. congrats so for thanks guys, the Hey on much question, taking and the

You for of for guys prescriptions Arcalyst noted written months. are that being XX two-thirds

the on type patient are for, XX-month Thanks For types prescription? the prescription versus are of other the written and that trends are being so any a what there duration another getting much. duration one-third, prescriptions

Sanj Patel

Ross, that? take do you want to

Ross Moat

that Hi, patients had of is--you speak were are for physicians we to. happy how thinking two-thirds see the duration pleased insight Yes, of very Yes, much the to and so good a thanks months for Nice very that’s duration, you prescriptions to question. the to know, about XX again. because into which therapy.

the Particularly there would just obviously really physicians follow-up with outside interpret to to to happen doesn’t are a of sure but so treatment months. see the from patient there, That it of was time, really the expecting For of therapy not new two-thirds XX how have expecting patient these and it obviously for prescribing again, physicians that first be or duration the moreover months, of their many for in so they’re and the that reassessing into again clinics, they patients be remaining answers what are so that they it. Arcalyst, one-third, they be the for and comes understanding to those in duration physicians term. that making patient. down prescriptions see as there would necessarily months expect the baseline three might closer to six that could want be follow-up part may Hopefully than the longer follow-up

which are that to disease and such are correlate patients patient In duration. of terms difficult of moment there stages in what the early and launch which trends think patient the low types, it’s at I numbers getting

The But that’s so the and patients targeted suffering are course, that’s duration doesn’t really not and question types clinically either that through see we suffer being there, and be. of is correlation necessarily from We again, there study it and we’re the the look if treatment that right though to really is they’re that coming speaking of patients we forward we of but actual to patients what’s eventual from acutely they once long that continued is midterm, steroids, two coming duration or actual that disease need rebound time in extension on that the chronic in where disease of symptomatic, duration in depend early the come. two I the broadly know from be duration will that’s so too ultimately do in will going to treatment, see the disease disease more to the eventual tell the time now treatment we response, we and treatment our difficult what reporting so different seeking into is term to of categories are mean continued prescribed, and then always What sure patients. even coming also therapy, to you risk patients a I’m results course duration patients stable, what think and probably patient’s that answer well. there’s is going symptomatic that’s are from that see average as there’s main a stop seeing.

Anupam Rama

for taking questions. much Thanks so our

Operator

you. Thank

Our question comes Paul Sachs. next with from Choi Goldman

line Your is open.

Paul Choi

Thank being to for on into and congratulations quarter our is regard doctors my maybe on first you much questions, My hesitancy well. you just access clarification? see it add they patients very any particular commercial. comment or question as on cited you let pieces for Is go to as can me looking or here, the taking as what get information factors With just Arcalyst? are onto primarily or reimbursement, are potential RP other of

Ross Moat

very take happy thank as much for I’m question hi that well you - that. to Paul,

Outside they’re see to the waiting more up healthcare or there this still previous we of first or terms hesitancy follow and a that experience of professionals. will how it’s of patients. early patients that, see again on comments in be is In probably wanting about goes they’re and the see the just hesitancy early doctors doing to of know, into physicians, the I launch, necessarily the headwinds for and think don’t see to It’s barriers from so the prescribe, on treatment. just--you appropriate relatively for stages many it

this continue think pericarditis, through, meetings see the [indiscernible] and we’ve so uptake prescribing. [indiscernible] approved and that’s particularly is physicians, people to and drug Of for physicians, seen Access far we’re reasonably a so on we’ll successful but do new treatment markets, very having disease and of successful we with in patients recurrent lot to question when rates. side and need now a of rare payor a flaring reimbursement of approval treatment is this first and quite disease, the is when what we a aware always really course, make a do things the come for is in education

up more broadly cases million we now place all therapy as we XX% approved, physicians XXX than confidence more covered U.S., payor in provide and also possible. of coverage lots mentioned, get much as quickly as hopefully across more and we onto approval speed the patients will have completed that still time As for now as well to lives with of have that the than

Paul Choi

Okay, understand timing thanks II and the also you IL-XX, question and of initiation in trial Ross, could if development on so on you’re their how for trial data secukinumab? for pipeline, the status and plans Novartis maybe much. that’s I Phase missed don’t the the on mavri what I helpful. announcing update think can Phase you so is is recently this very it Then and design, maybe slides here, but I thinking just us thinking know III you us about maybe GCA, the of trial then for of Thank the potential help here in and positive forth Eben. context

Sanj Patel

true few results is pleased question Sanj. that in had be we’re very a this and potential John, GCA II I’ll make a differentiation directed Paul, to would comments. Thanks better but Phase showed for there. really the with we Maybe Obviously the

give for you. our idea timing the next designs. to terms in but over as on to John we’ve or of you potential disclosed have GCA, immediately what John, disclosed not can in an commented trial past steps We for

John Paolini

a trial which with THXX is We there to safety III, moving of Agency I the Phase again. be both what discussed the gamma data, said sufficient still trial, in relapsing results onset aware we’ve for for data, replication III of well driven and Phase sorry, we patients, Then is Sure, be data II THX which especially they the The interferon, simple what XX nice do that of that weeks design regarding it in make recent is of design, a presentation do differentiating GMCSF, always that pivotal with that Phase refractory happy pathophysiology of according could you THX the is and being discussed talk BLA. exposure, the have ICH the is as a idea included forward good appear new with the single or importance to a--I’m as by the that targeting With for database a and and of the that to the a we’ve we to mavrilimumab, to with positive as sure the patients. well with think clinical believe trial, could regard XX-week was of before mavrilimumab. that, as which disease, a the positive both we’re as result, the guidelines. as yes, secukinumab be disease cytokine data to

depend program will the in but that forward. course, clinical results, confident going we’re Of our upon

Sanj Patel

I we think we’re having Should onto the next move some still there? technical difficulties. you’re if question, Operator,

Operator

Yes, thank you.

we Next of Meacham Geoff have BoA.

is open. line Your

Jason

for and in expectations of was everyone. wings? A that what how of so our great at color morning these us are dynamics the on if extent you taking were treated, patient Thanks This evolving? assistance transitioning Can you the very what help least to your will. the much. patient for would for were Any where Geoff. and Jason patients forward? majority there studies, the new? be Were sort patients, moving are there were helpful. that they is somewhat quarter. net things I who changing, understand refractory much and Thanks disposition, heavily rilonacept, sort Then of the payor may, from moving, of over gross these if or were clinical kind patients were the questions on the is Good and on To question current so for

Sanj Patel

can but Sanj. the then see can and, more Obviously this jump Ross a an I’ll where if early you Mark in to aren’t make be and hand I’m we of still in. specific or providing analysis we’re so to stage, is on that’s stages he and I’ll effusive, this bit opening quite Maybe at over that. net Jason, comment as or is any Ross gross at. fluid expect, wants launch to guidance

Ross Moat

think I absolutely you’re Yes, correct, Sanj.

we copay We’re that specific to net gross can a help provide guidance related that, not goods. many to payor percentage free patients moving what prescriptions, bit in less the we to meaning less what of the reached actually is to some discounts, copay and in mix, applied launch as well, QX, providing way little the the that patients so found buckets Arcalyst there benefit and was that favorability QX the already to higher the commentary actually well. commercial also the their that expected so a to through prior from probably is with we lower of did on as insurance meaning in on in of had I government the than to supports forward copay that any there commercial and part guess around we maxes the year the expected side statutory than QX, utilization launched leading stronger payor opposed I insurance

Of future course, at I’m on. fluid will things and as the very sure this is and of launch, quarters go season normalize the time

QX so we’re important into comfortable that the providing early to trends we’ve I experiences takes think that it’s that say our guidance. and launch in account seen, guidance

and bridge well our as a determination SG&A program opposed patients people captured the for in in Under patients, to start we’re patients whilst One for to mentioning worthwhile may free much are offerings Kiniksa be help on access patient that gross for insurers, gain who In goods program, net. that’s is sales Connect, making and possible. affordability goods, sure also, quick different terms waiting under important access services us. assistance very they’re it’s so as have to we keen program to do of coverage free line as available to actually also eligible between for incredibly patients, eligible our our patient marketing patient and But

in transition and prior we term so happened what patient to of coming XX% U.S. in happened, the the extension part, commercial opposed and to patients patients term beyond and that, on the already for new seen through launch, time. this now, disposition have of earnings the On moved the so that’s really around release, so to across really really long extension it quarter the QX coverage first the in first announced commercial we’ve long is Arcalyst was QX, prescribed drug,

also patients steroid focus - out the that we’re continue early very patients there so it’s received too groups. to comment on of buckets how of to but core the prescribe Arcalyst also really XXX each than the of we allows pericarditis, best We the are happy on cognizant to patients to have patients, the our refractory, with early of payors the in and in so so that but the many relapsing as team stages actually continue those the how just well, the field, dependency since we XX,XXX been within fill everything quarter guess perspective probably launch, a a marketing we’re base exactly very broad which a from pleased we’re be launch, very and physicians and of it’s do we more both prescribed have I of as that’s multiple and patients, patient and first kind focused time on physicians the is that launch digital of be the numbers. doubling now and with FDA, flexibility where number it’s focused the label on achieved at we the time of in from recurrent think which physicians they approval going that help the to

Jason

so you thank it, Got much.

Operator

you. Thank

Nierengarten we have David Next Wedbush. of

Your line open. is

David Nierengarten

for time trends thanks in see on for have Arcalyst the some any coming the or period there, the there term is I patient patients shorter How pace? for mean patients the actually, coming two, you the as to who on for in shorter Phase recurrent long pericarditis a vixa, information is in just any if have you for on are environment taking recurrent Hey, really question of time, are or therapies patient--you for curious on I’m time. therapy question. pericarditis, the diagnosis? a starting been of current recruitment? one slowdown on in patients, recruiting other the Thanks. going know, patients are is since are that study period on IIb, my there is second Then towards

Sanj Patel

Thanks David. jump I Ross, the in vixa. John in, can jump that for do starting and me a you want crack can take to at or or always

Ross Moat

happy very for much Hi very the thanks question. Yes, to. David,

you suffering more have trial, well, duration of on patient of already in that variable the if through to into underlying the plays I treatment like very the so we those of that the support saw terms points. entry the our dependent I providing shows data as prescribed now patients inflammation on really disease was and really get of and course best auto versus right time had adequate study, where metrics from. as pericarditis two In then goes the for that a on around that time pericarditis, make at recurrent at of naturally launch recurrent the guess just patient that that yet, we severe, it’s are messaging disease One and the population can the duration mean into two wanting that the Arcalyst, ultimately to they’re and when early RHAPSODY sure history highly marker and natural like, changes being any that they that maybe stage on, of but have patients type, not the patients is mean the look years, see when around of X.X duration had years, you we the duration provide is of been of duration

Sanj Patel

Does Arcalyst, that David? your on cover question

David Nierengarten

does. it Thanks. Yes,

Sanj Patel

ranging our jump next data and I we’re underway study, vixa, the Phase which Vixarelimab, Good, to well IIb expect year. dose and as on of we said with maybe John, I’ll obviously on we’ve second free start half in. said, feel

is believe there a We and expect study so else that and obviously we IIb to the starting a by continue ongoing any on we and can this you’ve half. in global unmet to enrollment at Europe execute anything no trial? it’s well, so is have disease, and point tend John, up endpoint, U.S. a say point, the XX-week to data is prurigo think need two-year in are The is second I and got backdrop. I that’s very the efficacy maybe or all the time know, driven the you significant landscape primary devastating the study nodularis, on is if and which obviously the approved key Phase currently But in Asia, we comments therapy,

John Paolini

lesion also--you No hit as by think Maybe itch you about the driven the trial endpoint, XX-week the is it NRS importantly reductions I efficacy a lesions. primary in of last a IGA X/X which well almost point or resolution Phase rapid given Sanj, the secondary nail showed itch design. the a saw terms attainment in endpoints, worst that the clear from or rapid side, worst the program, head IIa and endpoint, you of as the we as there in clear is on know, data as IRS, endpoint mentioned, then one

David Nierengarten

Got you. it, thank

Operator

you. Thank

Next we Liisa of Bayko Evercore. have

Your line is open.

Liisa Bayko

there’s rilonacept. the How one what is Hi, long. comment just projecting first therapy Two XXXX, XX think median now extension, a taking just know and when which be, the to of for thinking quite term the on of at thanks is about the for great about are here I you anniversary the months, it’s going one-year was we questions and long beyond duration duration the me, quarter. question, helpful

this would think beyond? you on beyond How range was that months being is prescriptions XX the nine about evolving thought to certainly duration your nine of for from six ’XX have think so six as we now months? is help You duration, us and the to written for months that initial - about thinking

Sanj Patel

to you, Over Ross.

Ross Moat

you Liisa, very questions. for much thank Hi thanks Sanj. the Yes,

be duration know telling to helpful we are I what dependent I going outside six point that, duration, the disease. But moving necessarily I duration mentioned. time we that so potential said, and around the early think number as actually the be. away eventual of QX is you wouldn’t unknowns the difficult go there a patients say disease, meaningful who the when mark, we patients of as duration that in QX of the going the still reaching course to upon it’s are so nine that where of to from is month particularly into but we stage, now, what we’re the acknowledging some to previously, we’re have of Regarding at it’s guess are just discussed

to term We out you’ll have out the long of of XX the that snapshot a we into time closed XX one-year long study the and continue on and the study, of patients this of extension, patient is nine Earlier two of when at--a the point long decided months look of the requirements. in withdrawal remember insights - so randomized withdrawal we slides and an point there Phase the trial XX of portion extension patients right anniversary the of median III showed one duration. portion for a of was start had of remember the months insight the the one that those randomized clinical therapy, opportunity long term that and go the physician now the at term the those depending is that extension had we term XX on that to is year, extension at months, study, look had and the duration additional up was median the on

is real the on writing months, you The therapy, duration weekly ultimately, in to some well gives regime one going prescribers they willingness patients maybe the of that mentioned physicians a payor about around well indication the second the which seeing. insight also two-thirds XX in are as the it just on really depend patients approval as they’re that thinking it’s world where But well. as on how stay are to for course disease as their for we’ve as

say of away won’t but little provides a now what moving tell we’re [indiscernible]. we’ve time right of on lot our previously, from an but I into there’s bit you hopefully it. uncertainty a there, will that said I insight that thinking think

Liisa Bayko

Now just for done you’ve kind stopping as don’t any for market a follow-up you the to trigger if that, in research of but this, physicians? I therapy seeing, the--what what is know are

Ross Moat

don’t haven’t academic on whether that, over to else. ceasing that we I want right take so of now. of treatment But haven’t that’s that, around help. taking the context outside some any MRI, [indiscernible] through around you shared place anything extra work might which provided know John, on anything Yes, we that point provide and

John Paolini

Liisa, help you with speak to again. nice to and out, happy Sure,

how that it’s raise You to this disease interesting an longstanding is physicians points and epidemiology monitor question, a said several do understanding the a--you is Ross years know, which patients, as of duration.

is safe underlying--whether a So resolved auto inflammation not that withdraw the and a they’re the treating an does well, patient interesting doing has you raise physician which that therapy. how underlying they’re or to it’s when chronically know and question,

the I is it where trials continued and that’s data because disease really that results recurrence. if premature as pericarditis in present, clinical of treatment response, the causes still think continued really clinical fact well underlying unmasks treatment helpful cessation that are showed disease underlying the in resulted the as or

some clinically terms the of so markers to they the the kind information pieces are has, patient really--it’s difficult In two a of that that of look using. are physician cardiologists least that reach some of there and conclusion, at at expert of

of the the therapy of disease where in has at is the and let’s and rilonacept point, baseline. long is the is time that they is you first disease look course of recurrences of that well the initiated, at say of co-morbidities. one until it severity one to looking density associated how approach, some in therapy terms initiated, disease up as at number their as lasted patient the at and That’s see The are their the

therapy, and helpful. clinicians continue as a helpful that study, that well have there that therapy that the to indicator hyper Phase both that two called, is a enhancement, II associated what of from the currently basically of with is are be there’s data phenomenon point insights. technologies and Phase underlying can shows on it’s hyper that’s study neovascularization that cessation shows as substrate Clinic still present, be the which an Again, shown that is has at to a shown III when is called while support the from what could this define was fact as delayed and the--the shown burden autoinflammation present, have the look hope to well are been Another help the some Cleveland shown so delayed imaging approach enhancement, we’ve the pericardium, on therapy, Those with the data factors is inflammation, and patient a as so I and of whether to that that available recurrence. of to higher data is

Liisa Bayko

how there recently, me some and PN. for Very dupi a lot. so, see landscape data or the just comment that question competitive evolving. you was the helpful, last you could final know Then a thanks over I and from Maybe on on vixarelimab, week

understand, you that of data I NRS some as landscape? are score, of the lesions how saw kind thinking temporary and As a and the they nice or competitive resolution Thanks. also dupi of in we should pretty benchmark, think a

John Paolini

to jump on Sanj, would you me like that? in

Sanj Patel

Yes, go ahead.

John Paolini

sure. Okay,

with we’ve data We’re for data we other they’re aware dupilumab data dermatitis. is consistent from dupilumab see of the what seen pretty and much with atopic example the program, with in what the that

then therapy. resolution before. what prurigo consistent in also was what bit a profound we gradual inflammatory that weeks a course in so there they to initiation so differentiated vixarelimab pruritis and of saw is a and that action much a the lesions, dupilumab THX term is for nodularis interleukin-XX you space early As the that lag and is first think and responses, know, in blocks which of I that’s resolves is we it reason this over helpful dataset see blocking why more seen and saw the reduction more we atopic trial scores. results after see there inflammation what We dermatitis of we rapid the showed, pruritis a the time of so and because then reduction long a in believe over reduction interleukin-XX certainly that vixarelimab time, see we’ve in is Similarly in levels, of scores with even of the directly, the the

that’s a clear nearly hope our X clear remember week also from week of of was I If across - it comparison or achieved helpful X, but IIa had the early you’ll saw as we was data, a significant Phase patients that almost data, as understanding it’s early at X. separation trials. at week curve with statistically significant third

Liisa Bayko

thank very Great, you much.

Operator

speakers, return for you Thank comments. questions in so see closing the I call the to back no I you. further queue,

Sanj Patel

to Thanks do. great Operator. a joining obviously a more lot for today, Thanks everybody in quarter,

both well about we’re bye Arcalyst bye. the as pipeline, on. excited crack and as to Thank very you, We’re going

Operator

all conclude Thank This for participating. you conference call. today’s does

may have and pleasant day. You now disconnect a

Kiniksa Pharmaceuticals (KNSA) 1 Nov 212021 Q3 Earnings call transcript